Maria Vamvini is an Endocrinology/Metabolic physician affiliated with Joslin Diabetes Center. OpenAlex indexes 47 publications with 1,838 citations (h-index 13); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingClinical trials
- Exercise, Brain Activity, and Weight Maintenance
Sponsor: Joslin Diabetes Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
72.6%GLP-1 receptor agonist20.5%Trulicity58%Ozempic42%Part D≥16 patientsInsulin Analog18.7%Tresiba Flextouch U-10025%Lantus Solostar23%Novolog Flexpen23%Tresiba Flextouch U-20016%Insulin Lispro Kwikpen U-10013%Part D<11 patients+ 5 more classes in this area
Hormonal (systemic)
18.7%l-Thyroxine14.8%Levothyroxine Sodium75%Synthroid25%Part D<11 patientsThyroid Hormone Synthesis Inhibitor3.9%Methimazole100%Part D<11 patientsCardiovascular
5.5%Statin5.5%Atorvastatin Calcium100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2020–2021 per NIH RePORTER. The latest:
- Multi-omics approach to understanding the beneficial effects of exercise in diabetes
Joslin Diabetes Center
FY2021$81,642F32DK126432 - Multi-omics approach to understanding the beneficial effects of exercise in diabetes
Joslin Diabetes Center
FY2021$65,319F32DK126432 - Multi-omics approach to understanding the beneficial effects of exercise in diabetes
Joslin Diabetes Center
FY2020$80,358F32DK126432
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Design of debunking the frailty–sarcopenia–ADT axis in metastatic prostate cancer with multicomponent exercise: the FIERCE trial protocol
Frontiers in Sports and Active Living
2025 - Type 2 Diabetes and Obesity Alter Exercise Training-Induced Transcriptional Adaptations to Subcutaneous White Adipose Tissue
bioRxiv (Cold Spring Harbor Laboratory)
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Lloyd Aiello, MD, PhD
Joslin Diabetes Center
Sylvia Rosas, MD
Joslin Diabetes Center
Jason Gaglia, MD
Joslin Diabetes Center
Mary Horlick
Joslin Diabetes Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”